Loading
institutionsInstitution
Tianjin Medical University Cancer Institute and Hospital
The birthplace of Chinese oncology (an 1861 mission hospital, made a cancer hospital in 1952 under Jin Xianzhai) and a national centre for breast and pancreatic cancer.
Also called: TMUCIHTianjin Cancer Hospital天津医科大学肿瘤医院
Overview
TMUCIH traces its origins to 1861 and became China's first specialised cancer hospital in 1952 under Jin Xianzhai, the founder of Chinese oncology. It is a national clinical research centre for cancer, hosts the Key Laboratory of Cancer Prevention and Therapy, and runs one of China's largest breast cancer programmes alongside strong pancreatic, lung, head and neck and gynaecological services. Its epidemiology group produces long-running cancer incidence data for Tianjin, and the hospital has been an early adopter of intraoperative radiotherapy, tomotherapy and robotic surgery. It is a frequent lead site for Chinese breast and pancreatic trials.
Location
Tianjin, CN
Type
cancer center · Tianjin Medical University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#216 · 28 points (0 Newsweek + 0 NCI + 28 from 14 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Tianjin Medical University Cancer Institute and Hospital, including child institutions. 1,219 works · 11,455 citations · 72% open access · 21% clinical trials · 2% reviews.
Oncology works per year
2002022
2582023
2432024
2932025
2252026
Most works
- Jihui Hao40 works
- Yi Ba34 works
- Xiubao Ren34 works
- Ying Cheng33 works
- Zhongsheng Tong29 works
- Dingzhi Huang26 works
- Huilai Zhang24 works
- Aomei Shen24 works
- Lujun Zhao21 works
- Lin Wu20 works
Most cited
- Breast cancer
- Pancreatic cancer
- Cancer epidemiology
- Radiotherapy technology
Similar pages
- CompanyTherapixel
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyVara
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- JournalJournal of breast imaging
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyVolpara Health
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyKheiron Medical Technologies
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TrialTMIST (Tomosynthesis Mammographic Imaging Screening Trial)
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- IdeaOne-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit
Shares Mammography & tomosynthesis, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TrialTARGIT-A (targeted intraoperative radiotherapy)
Shares Intraoperative radiotherapy (IORT), HER2-positive breast cancer, IMRT / IGRT (modern external beam), Triple-negative breast cancer (TNBC).